← All stocks

ORAMED PHARMACEUTICALS INC.

ORMP Net selling

CIK 0001176309 #3940 in the set updated 17 Sep 2026

Bought (12 mo)

$0.00

out of their own pocket, the only kind of buying there is

Sold (12 mo)

$942.17K

$0.00 on a plan · $0.00 straight out of an exercise

Sold at will

$942.17K

2 of 2 sales

Net

−$942.17K

−$942.17K against sales at will

By person

9 insiders · 3 transactions

24.9×

Nadav Kidron holds 24.9 times base salary in stock. $15.43M of shares against $619.53K in salary for 2025.

Salary from the company's own proxy. The shares are what Nadav Kidron last reported holding, valued at $4.51, the price Common Stock was last bought or sold at on the open market here, on 1 Jul 2026.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Hexter Joshua

COO & CBO

—

$611.43K (1)

−$611.43K

1,073,384

2.58%

$4.84M

+122.8%

Gabay Avraham

Chief Financial Officer

—

$330.74K (1)

−$330.74K

671,785

1.61%

$3.03M

+379.7%

KIDRON NADAV

President and CEO

—

3,422,243

8.23%

$15.43M

+87.4%

Kidron Miriam

Chief Scientific Officer

—

1,133,138

2.72%

$5.11M

+33.3%

Mayer Arie

Director

—

168,009

0.4039%

$757.47K

+74.8%

Sank Leonard

Director

—

134,531

0.3234%

$606.53K

+37.2%

Shapiro Benjamin

Director

—

123,220

0.2962%

$555.54K

+123.8%

Aghion Daniel

Director

—

113,441

0.2727%

$511.45K

+192.2%

Reznick Yehuda

Director

—

105,180

0.2529%

$474.20K

+244.2%

Individual transactions

Insider

Date

Role

Action

Price

Amount

Gabay Avraham

1 Jul 2026

Chief Financial Officer

Sell

73,360

$4.51

$330.74K

Hexter Joshua

1 Jul 2026

COO & CBO

Sell

137,000

$4.46

$611.43K

Show all 3 transactions →

What was left out

Form 4 filings counted 22

Amendments (4/A) skipped 0

Filings about a different issuer 0

Unreadable filings 0

Joint filings 0

Sales on a Rule 10b5-1 plan 0

Sales straight out of an exercise 0

Sales at will 2

Transactions with no price 0

Shares from compensation/vesting 2,705,824

History held since 7 Nov 2016